Wayne State University

1. Genentech, Inc. $1,186,491 125 payments
2. Pfizer Inc. $990,160 201 payments
3. F. Hoffmann-La Roche AG $686,541 134 payments
4. Novartis Pharmaceuticals Corporation $667,646 43 payments
5. AbbVie, Inc. $448,752 198 payments
6. Ucb SA $411,434 37 payments
7. Genzyme Corporation $399,433 68 payments
8. Instrumentation Laboratory Company $389,079 1 payment
9. BioMarin Pharmaceutical Inc. $266,690 90 payments
10. Agios Pharmaceuticals, Inc. $251,229 94 payments

1. A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $396,386 29 payments
2. Roll Over Protocol for 3 Ocr Pivotal Studies Opera I Opera II and Oratorio to Extend the Ole $361,499 114 payments
3. Assessing Disease Activity in Minority Patients With Relapsing Multiple Sclerosis Using Ocrelizumab $335,144 29 payments
4. Second Phase III in RMS $325,042 20 payments
5. A Two Year Double Blind Randomized Multicenter Active Controlled Study to Evaluate the Safety and Efficacy of Fingolimod Administered Orally Once Daily Versus Interferon Beta 1A I M Once Weekly in Pediatric Patients With Relapsing Remitting Multiple Scler $239,826 4 payments
6. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients with Heart Failure and Impaired Systoli $197,375 3 payments
7. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $185,280 53 payments
8. A Phase 2B Randomized Doubleblind Placebocontrolled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4 Antigen Vaccine Sa4ag in Adults Undergoing Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation $165,513 16 payments
9. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $156,824 23 payments
10. Randomized Phase II Screening Trial of Enzalutamide/Mdv-3100 and LHRH Analogue VS Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer $151,065 7 payments

1. Patient care $44,479 4 payments
2. Other $35,531 8 payments
3. Overhead $3,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.